This extreme truck created by Rezvani Motors has 6 wheel drive, a 1,300 Horsepower engine, and military grade bulletproof armor protection features.
This extreme truck created by Rezvani Motors has 6 wheel drive, a 1,300 Horsepower engine, and military grade bulletproof armor protection features.
The taxes you owe on your 401(k) distributions at retirement depend in large part on whether your funds are in a traditional 401(k) or a Roth 401(k).
Well, it’s official. Joe Biden is now President, and he’ll be backed – at least for the short term – by Democratic majorities in both Houses of Congress. Wall Street is taking the measure of the new Administration, and sees, among its first moves, a boost in fiscal stimulus that is likely to goose consumer spending, bump corporate profits, and provide general economic support in the first half of 2021. Covering the situation for Goldman Sachs is investment strategist David Kostin, who is bullish on the near-term prospects for fiscal stimulus. In light of it, Kostin sets the Goldman outlook for this year at 6.4% GDP growth; he sees continued high growth next year, and sets the 2022 prediction at 4%. These outlook numbers are up from the previously published 5.9% and 3.7%. To this end, Kostin sees S&P 500 reaching 4,300 by year’s end, which would be a gain of 12% from current levels. “Elections have consequences. Democratic control of Washington, D.C. after January 20 will bring greater fiscal spending, faster GDP growth, more inflation, and higher interest rates than we had previously assumed,” Kostin noted. With markets looking up, investors are looking for the stocks that are ready for gains. Penny stocks, equities priced at less than $5 per share, are a natural place to search for potential winners. Their low price means that even a small incremental gain will translate into large percentages. However, before jumping right into an investment in a penny stock, Wall Street pros advise looking at the bigger picture and considering other factors beyond just the price tag. For some names that fall into this category, you really do get what you pay for, offering little in the way of long-term growth prospects thanks to weak fundamentals, recent headwinds or even large outstanding share counts. Taking the risk into consideration, we used TipRanks’ database to find compelling penny stocks with bargain price tags. The platform steered us towards two tickers sporting share prices under $5 and “Strong Buy” consensus ratings from the analyst community. Not to mention substantial upside potential is on the table. AzurRx BioPharma (AZRX) We’ll start with a company specializing in gastrointestinal disease, AzurRx. This company is focused on creating non-systemic, targeted recombinant therapies for GI ailments. AzurRx has a pipeline of three drug candidates, at several levels of the development process. The key pipeline candidate, MS1819, is being investigated as a treatment for exocrine pancreatic insufficiency for patients also suffering from cystic fibrosis. MS1819 is a recombinant lipase, derived from a yeast strain. The drug is designed to target fat molecules in the digestive tract, allowing patients to absorb the broken-down fats for nutritive value. The drug is currently in Phase 2 trials, which are scheduled for completion in the first half of this year. As of January 21, the first two patients in the Phase 2b OPTION 2 extension study have been dosed with the treatment, and the Data Monitoring Committee (DMC) “remains supportive of the program.” In another important development, AzurRx announced earlier this month that it is entering a partnership with First Wave Bio to study oral and rectal formulation of Niclosamide to treat immune checkpoint inhibitor-associated colitis (ICI-AC) and COVID-19 related gastrointestinal infections. The estimated market for Niclosamide as a treatment for COVID-related GI problems exceeds $450 million. Based on multiple potentially significant clinical catalysts as well as its $0.98 share price, several members of the Street think that now is the right time to pull the trigger. Jonathan Aschoff, of Roth Capital, is bullish on AzurRx, basing his longer-term forecasts on the probable success of MS1819. “We base our valuation for AZRX on projected future U.S. sales from MS1819 for the treatment of EPI due to CF and CP, using an initial annual price of about $18,000, a price that is consistent with currently available PERTs. We project MS1819 to be commercialized in the U.S. in 2023, generating sales of $272 million in 2030. Ex-U.S. commercial success for MS1819, or commercial success from the early-stage beta-lactamase program would provide upside to our valuation,” Aschoff noted. The analyst also looks forward to initial clinical results of Niclosamide in COVID-19 GI infection and in ICI-AC potentially, noting: "Niclosamide was FDA approved in 1982 to treat intestinal tapeworm infections and is on the World Health Organization’s list of essential medicines. Given the millions of patients that have taken the drug, the safety profile has largely been established, thereby lowering developmental risk.” Given all of the above, Aschoff rates AZRX as a Buy, and his $7 price target suggests a sky-high 608% upside for the year ahead. (To watch Aschoff’s track record, click here) Overall, the analyst consensus on AZRX shares is a Strong Buy; the stock has 4 recent reviews, including 3 Buys and a single Hold. In addition, the $4 average price target brings the upside potential to 304%. (See AZRX stock analysis on TipRanks) ProQR (PRQR) ProQR is a biotechnology company focused on treatments for congenital progressive blindness. Specifically, the firm is working on medications to reverse a group of genetic sight disorders called inherited retinal diseases. These diseases currently have no effective treatments. The company has a research pipeline of five drug candidates, in varying stages of the research process. The two that are farthest along are QR-110 (Sepofarsen), and QR-421. Of those two, QR-110 is currently in Phase 2/3 studies. This candidate is an RNA therapy designed to correct the most common CEP290 gene mutation causing Leber congenital amaurosis 10 (LCA10). This is a severe genetic retinal disease that affects as many as 3 in 100,000 children. QR-421 is another RNA therapy, this one focused on exon 13 mutations in the USH2A gene. These mutations cause blindness due to retinitis pigmentosa and/or Usher syndrome. QR-421 is in Phase 1/2 studies, with an aim of restoring lost vision or preventing the loss in the first place. Covering the stock for JMP, analyst Jonathan Wolleben points to Sepofarsen as a key component of his bullish thesis. “We continue to feel good about sepofarsen’s chance of success in Illuminate for multiple reasons: 1) Phase 1/2 confirmed the target registrational dose and dosing interval (6 months); 2) patients had clinically significant and durable BCVA improvements after 12 months – pivotal primary endpoint; 3) supportive secondary efficacy measures (FST, mobility); 4) similar responses seen in second treated eyes; 5) long-term safety confirms positive risk/benefit; and 6) Illuminate patient population was enriched based on Phase 1/2 results (baselinevision of >/=hand motion). We assign sepofarsen a 60% POS and model LCA10 as an ~$300M opportunity to PRQR at peak penetration," Wolleben opined. In line with his upbeat outlook, Wolleben puts a $20 price target on the stock, implying a 384% one-year upside, along with an Outperform (i.e. Buy) rating. (To watch Wolleben’s track record, click here) All in all, PRQR gets a unanimous Strong Buy rating from the analyst consensus, based on 3 positive stock reviews. Shares are currently trading for $4.13, and their $20.67 average price target is slightly more bullish than Wolleben’s, suggesting an upside of 400% for the coming 12 months. (See PRQR stock analysis at TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The financial expert and radio host says these money blunders can be costly.
With the Biden Administration likely to pump trillions into green energy infrastructure in the coming years, renewable stocks should outperform the market
Futures fell Friday morning. The stock market rally hit new highs Thursday on big techs like Apple, AMD and Intel, but an increasingly extended Nasdaq raises risks.
Greenlight Capital hedge fund manager and notorious value investor David Einhorn just released his annual letter to investors, which revealed a record quarter for Einhorn to close out a difficult 2020.Finishing Strong: Greenlight took a massive hit from a large short position in Tesla Inc (NASDAQ: TSLA) in 2020, but Greenlight finished strong with a 25% gain in the fourth quarter. Despite the disastrous Tesla short position, Einhorn was able to salvage a 5.2% overall gain for the fund for the year.The Greenlight letter disclosed several new long positions heading into 2021, including Fubotv Inc (NYSE: FUBO), Danimer Scientific Inc (NYSE: DNMR) and Neubase Therapeutics Inc (NYSE: NBSE), according to Bloomberg. All three stocks were trading higher by more than 10% on Thursday.Einhorn said the Tesla short position was Greenlight's biggest loser in 2020, although he reportedly adjusted the position prior to Tesla's inclusion in the S&P 500.Related Link: Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their PortfoliosEinhorn's Recent Struggles: Greenlight has significantly underperformed the S&P 500 in recent years as growth stocks have soared and value stocks have lagged. Greenlight reported a 14% net gain in 2019 following a 38% net loss in 2018, its worst year since the fund's inception in 1996.Einhorn gained mainstream notoriety on Wall Street back in 2007 when he disclosed a short position in Lehman Brothers prior to the bank's collapse in 2008. However, he had drawn a lot of criticism in recent years for his persistent short position in Tesla and his often heated public communications with Tesla CEO Elon Musk."TSLA cars are not a fad; if they were, TSLA would sell many more than it does. The fad is in owning TSLA stock," Einhorn said in the letter.As of the end of the third quarter, Greenlight's three largest long positions were Green Brick Partners Inc (NYSE: GRBK), Brighthouse Financial Inc (NASDAQ: BHF) and Atlas Air Worldwide Holdings, Inc. (NASDAQ: AAWW).Benzinga's Take: Economist John Maynard Keynes famously said "the market can stay irrational longer than you can stay solvent," and Einhorn's performance in recent years highlight just how much of a toll a single short position can take on an entire portfolio when the stock in question gets caught in a potential market bubble. Short positions can result in unlimited theoretical losses, whereas standard long positions are capped at just 100% downside.Image credit: PokerListings, YouTubeSee more from Benzinga * Click here for options trades from Benzinga * Why This Enphase Energy Analyst Is Bullish Following Tesla-Driven Sell-Off * Here's How Americans Are Spending Their Stimulus Payments(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
In the case of the electric vehicle industry, the line should go: They are coming so you better build it. Auto makers new and old are planning to launch dozens of fully electric vehicles in the coming years, capitalizing on the incredible success of (TSLA) (ticker: TSLA). For EV adoption to continue to grow at a rapid pace, charging infrastructure will also need to keep up with vehicle sales.
Easing COVID-related restrictions has helped reverse the decline in oil demand and prices, which remain steady since a late-2020 rebound from historic lows. Like its rivals Halliburton Co and Baker Hughes Co noted earlier this week, Schlumberger Chief Executive Officer Olivier Le Peuch said on Friday he was optimistic about demand recovery through this year, giving investors hope that the oil downturn is nearing an end.
Be wise with how you allocate your money, $730 million Powerball winner.
Chinese EV maker XPeng picked up a short-term buy rating, but it isn’t because the EV market is hot—even though it is.
A couple of months ago at CNBC’s Transform conference, IBM CEO Arvind Krishna painted a picture of a company in the midst of a transformation. Meanwhile cognitive applications -- where you find AI incomes -- were flat. If Krishna was looking for a silver lining, perhaps he could take solace in the fact that Red Hat itself performed well, with revenue up 18% compared to the year-ago period, according to the company.
BlackRock Inc. said Thursday that it will raise its dividend by 14%. The investment management's new quarterly dividend of $4.13 a share, up from $3.63 a share, will be payable March 23 to shareholders of record on March 5. The stock slipped 0.1% in afternoon trading. At current prices, the new annual dividend rate implies a dividend yield of 2.23%, compared with the dividend yield for the SPDR Financial Select Sector ETF of 1.95% and the implied yield for the S&P 500 of 1.48%, according to FactSet. BlackRock's stock has gained 16.7% over the past three months, while the financial ETF has rallied 24.1% and the S&P 500 has advanced 12.1%.
2020 introduced the term “coronavirus stocks.” These are the companies working on solutions to fend off the Covid-19 global pandemic. As a result, several of the names involved in the hunt for treatments and vaccines accrued incredible gains throughout the year. With 2 vaccines already granted EUAs, and more on the way, it’s doubtful the same levels of enthusiasm could be attained for these stocks in 2021. Hold that thought, say investors of Adamis Pharma (ADMP). Shares are already up by a massive 160% this month, 78% of which were amassed in Wednesday’s session. The surge came after the company announced it has submitted an Investigational New Drug (IND) to the FDA for the use of Tempol as a treatment for COVID-19. Last June, Adamis licensed Tempol from Matrix Biomed, and in pre-clinical studies, the treatment has displayed strong anti-inflammatory, anticoagulant, and antioxidant abilities. In animal models, Tempol has exhibited the ability to lower proinflammatory cytokines (cytokine storm) and it has also shown it can decrease the genes correlated to hypoxia. Adamis believes reigning in hypoxia and the cytokine storm could be vital to the successful treatment of COVID-19. The company has indicated it expects to receive funding to initiate clinical trials, via the government’s Operation Warp Speed (OWP) program. Covering the stock for Raymond James, analyst Elliot Wilbur commented, "While we continue to view that the core of ADMP’s valuation is with the potential approval of ZIMHI – its high-dose injectable naloxone formulation for the treatment of opioid overdose – and FDA approved Symjepi, given the unmet need on the COVID-19 treatment front, we believe ADMP’s progress with Tempol could provide some positive upside to the name that isn’t fully priced into its current share levels." For now, Wilbur sticks to a Market Perform (i.e. Hold) rating without providing a price target. (To watch Wilbur’s track record, click here) Only one other analyst has reviewed Adamis’ prospects recently, also rating the stock a Hold. Therefore, the stock qualifies with a Hold consensus rating. (See ADMP stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Congressional leaders plan to get "right to work" on it. How soon might you get the cash?
Other auto stocks joins in the impressive rally in Tesla's stock. Here's why.
These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and the most momentum for February.
Q: When the inheritor of a Roth IRA receives the funds, is it true that the distributions would not be taxed? It would be unusual for any taxes to be due on an RMD from an inherited Roth IRA. The only portion of an inherited IRA that could be subject to tax is earnings.
My Pillow CEO Mike Lindell is the latest business leader to discover the downside of becoming a crank.
Both the S&P 500 and Nasdaq ended the regular trading day Thursday at record closing levels, and the Dow ended just short of its own record high.
Alibaba Group Holdings Ltd. (NYSE: BABA)-backed Ant Group's valuation is estimated to be around $108 billion, according to Bloomberg Intelligence.What Happened: This would be less than half of the $250 billion estimated valuation for Ant when it sought to go public late last year.China's draft proposals on financial technology is the primary contributing factor in this valuation plunge, as per Bloomberg analysts.Ant's popular payments service Alipay in particular could see its valuation halved under the regulations, as per analyst Francis Chan."Ant Group's valuation may plunge further if its payment unit is forced to break up due to potential anti-trust probes by China's central bank," Chan said.Why It Matters: Ant has faced trouble with the Chinese authorities ever since co-founder Jack Ma, the country's most-famed billionaire, made comments critical of Chinese regulations at an event in Shanghai in October.Ma was laying low in light of the increased scrutiny but reappeared in public for the first time in months, earlier this week.Price Action: Alibaba shares closed 2% lower at $260 in New York on Thursday.Read Next: Why Jack Ma's Reappearance Isn't Enough To Calm Alibaba InvestorsSee more from Benzinga * Click here for options trades from Benzinga * Why This Analyst Is Cautioning Bitcoin Investors To Have A 'Very Strong Stomach' Amid Plunge * Why XRP Is Outperforming Bitcoin Today(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.